

DAFTAR PUSTAKA

- Balfour, H. H., Fletcher, C. V., Erice, A., Henry, W. K., Acosta, E. P., Smith, S. A., *et al.* 1996. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. *Antimicrobial Agents and Chemotherapy* 40(12): 2721–2726.
- Bell, W. R., Chulay, J. D., Feinberg, J. E. 1997. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). *Medicine* 76(5): 369–380.
- Benson, A. B., Kaplan, J. E., Masur, H., Pham, A. P., Holmes, K. K. 2004. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. *Morbidity and Mortality Weekly Report* 53(RR-15): 1–111.
- Bigliano, P., Calcagno, A., Lucchini, A., Audagnotto, S., Montrucchio, C., Marinaro, L., *et al.* 2018. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. *Antiviral Therapy* 23(5): 451–456.
- Biron, K. K. 2006. Antiviral drugs for cytomegalovirus diseases. *Antiviral Research* 71: 154–163.
- Blank, B. S. N., Meenhorst, P. L., Weverling, G. J., Stout-Zonneveld, A. A. M., Pauw, W., Mulder, J. W., *et al.* 1999. Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients. *AIDS* 13(18): 2533–2539.
- Bowen, E. F., Sabin, C. A., Wilson, P., Griffiths, P. D., Davey, C. C., Johnson, M. A., *et al.* 1997. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. *AIDS* 11(7): 889–893.
- Bowen, E. F. 1999. Cytomegalovirus reactivation in patients infected with HIV: The use of polymerase chain reaction in prediction and management. *Drugs* 57(5): 735–741.
- Brosgart, C. L., Louis, T. A., Hillman, D. W., Craig, C. P., Alston, B., Fisher, E., *et al.* 1998. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. *AIDS* 12(3): 269–277.
- Brown, F., Banken, L., Saywell, K., Arum, I. 1999. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. *Clinical Pharmacokinetics* 37(2): 167–176.
- Cao, W., Mehraj, V., Kaufmann, D. E., Li, T., Routy, J. P. 2016. Elevation and persistence of CD8 T-cells in HIV infection: The Achilles heel in the ART era. *Journal of the International AIDS Society* 19(1): 1–9.
- CDC. 2018. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. *Recommendations and Reports* U1-U68.
- Chen, K., Cheng, M. P., Hammond, S. P., Einsele, H., Marty, F. M. 2018. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. *Blood Advances* 2(16): 2159–2175.
- Collazos, J. 2003. Opportunistic Infections of the CNS in Patients with AIDS. *CNS*

- Drugs* 17(12): 869–887.
- Cooper, D. A., Pehrson, P. O., Pedersen, C., Moroni, M., Oksenhendler, E., Rozenbaum, W., *et al.* 1993. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex. *AIDS* 7: 197-207.
- David Paltiel, A., Goldie, S. J., Losina, E., Weinstein, M. C., Seage, G. R., Kimmel, A. D., *et al.* 2001. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. *Clinical Infectious Diseases* 32(5): 783–793.
- Deayton, J. R., Sabin, C. A., Johnson, M. A., Emery, V. C., Wilson, P., Griffiths, P. D. 2004. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. *Lancet* 363: 2116–2121.
- Dotd, K. K., Jacobsen, P. H., Hofmann, B., Meyer, C., Kolmos, H. J., Skinhøj, P., *et al.* 1997. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. *AIDS* 11(3): 21–28.
- Drew, W. L., Anderson, R., Lang, W., Miner, R. C., Davis, G., Lalezari, J. 1995. Failure of high-dose oral acyclovir to suppress CMV viraemia or induce ganciclovir-resistant CMV in HIV antibody positive patients. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 8(3): 289-291.
- Drouet, E., Boibieux, A., Michelson, S., Ecochard, R., Biron, F., Peyramond, D., *et al.* 1993. Polymerase chain reaction detection of cytomegalovirus DNA in peripheral blood leukocytes as a predictor of cytomegalovirus disease in HIV-infected patients. *AIDS* 7(5): 665-668.
- Durier, N., Ananworanich, J., Apornpong, T., Ubolyam, S., Kerr, S. J., Mahanontharit, A., *et al.* 2013. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: Prevalence and associated mortality. *Clinical Infectious Diseases* 57(1): 147–155.
- El Amari, E. B., Combescure, C., Yerly, S., Calmy, A., Kaiser, L., Hasse, B., *et al.* 2011. Clinical relevance of cytomegalovirus viraemia. *HIV Medicine* 12(7): 394–402.
- Emery, V. C., Sabin, C., Feinberg, J. E., Grywacz, M., Knight, S., Griffiths, P. D. 1999. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: Baseline CMV load dictates time to disease and survival. *Journal of Infectious Diseases* 180(3): 695–701.
- Erice, A., Tierney, C., Hirsch, M., Caliendo, A. M., Weinberg, A., Kendall, M. A., *et al.* 2003. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). *Clinical Infectious Diseases* 37(4): 567–578.
- Feinberg, J. E., Hurwitz, S., Cooper, D., Sattler, F. R., MacGregor, R. R., Powderly, W., *et al.* 1998. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. *Journal of Infectious Diseases* 177(1): 48–56.
- Fielding, K., Koba, A., Grant, A. D., Charalambous, S., Day, J., Spak, C., *et al.* 2011. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral

- therapy among HIV-infected gold miners in South Africa. *PLoS ONE* 6(10): e25571.
- Florescu, D. F., Qiu, F., Schmidt, C. M., Kalil, A. C. 2014. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. *Clinical Infectious Diseases* 58(6): 785–803.
- Focà, E., Motta, D., Pollara, C., Brianese, N., Gotti, D., Albini, L., *et al.* 2012. Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naïve to antiretroviral therapy. *New Microbiologica* 35(2): 227–231.
- Fox, E. F., Smith, N. A., Rice, P., Dunn, H., Peters, B. S. 1998. Cytomegalovirus pp65 antigenaemia as an indicator of end-organ disease in AIDS. *International Journal of STD and AIDS* 9(9): 545–547.
- Francisci, D., Tosti, A., Baldelli, F., Stagni, G., Pauluzzi, S. 1997. The pp65 antigenaemia test as a predictor of cytomegalovirus-induced end-organ disease in patients with AIDS. *AIDS* 11(11): 1341–1345.
- Freeman, M. L., Lederman, M. M., Gianella, S. 2016. Partners in crime: the role of CMV in immune dysregulation and clinical outcome during HIV infection. *Current HIV/AIDS Reports* 13(1): 10–19.
- Gérard, L., Leport, C., Flandre, P., Houhou, N., Salmon-Céron, D., Pépin, J. M., *et al.* 1997. Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus. *Clinical Infectious Diseases* 24(5): 836–840.
- Gianella, S. dan Letendre, S. 2016. Cytomegalovirus and HIV: A dangerous pas de deux. *Journal of Infectious Diseases* 214(Suppl 2): S67–S74.
- Griffiths, P. D., Feinberg, J. E., Fry, J., Sabin, C., Dix, L., Gor, D., *et al.* 1998. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. *Journal of Infectious Diseases* 177(1): 57–64.
- Grzywacz, M., Deayton, J. R., Bowen, E. F., Wilson, P., Emery, V. C., Johnson, M. A., *et al.* 1999. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients. *Journal of Medical Virology* 59(3): 323–328.
- Hanley, P. J. dan Bollard, C. M. 2014. Controlling cytomegalovirus: Helping the immune system take the lead. *Viruses* 6: 2242–2258.
- Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., Welch, V. A. (editors). 2019. *Cochrane handbook for systematic reviews of interventions: 2nd edition.* Chichester (UK): John Wiley & Sons.
- Humar, A. dan Michaels, M. 2006. American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *American Journal of Transplantation* 6(2): 262–274.
- Humar, A. dan Snyderman, D. 2009. Cytomegalovirus in solid organ transplant recipients. *American Journal of Transplantation* 9(Suppl 4): S78–S86.
- Ioannidis, J. P. A., Collier, A. C., Cooper, D. A., Corey, L., Fiddian, A. P., Gazzard, B. G., *et al.* 1998. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: A meta-analysis of randomized individual patient data. *Journal of Infectious Diseases* 178(2): 349–359.
- Jacobson, M. A., Gallant, J., Wang, L. H., Coakley, D., Weller, S., Gary, D., *et al.*

1994. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. *Antimicrobial Agents and Chemotherapy* 38(7): 1534–1540.
- Jacobson, M. A. 1995. Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. *Scandinavian Journal of Infectious Diseases Supplement* (99): 96–99.
- Jacobson, D. L., Wu, A. W., Feinberg, J. 2003. Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease. *Journal of Clinical Epidemiology* 56(9): 874–879.
- Jaton, K., Muheim, C., Barbani, M. T., Sahli, R., Rudaz, P., Meylan, P. R. A. 1999. Detection of CMV DNA in peripheral blood leukocytes as a long-range harbinger of CMV disease in HIV-infected patients. *Ocular Immunology and Inflammation* 7(3–4): 147–157.
- Kalil, A. C., Levitsky, J., Lyden, E., Stoner, J., Freifeld, A. G. 2005. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. *Annals of Internal Medicine* 143: 870–880.
- Kemkes RI. 2019. Keputusan Menteri Kesehatan Republik Indonesia nomor HK.01.07/MENKES/90/2019 tentang pedoman nasional pelayanan kedokteran tata laksana HIV. 1–220.
- Kempen, J. H., Frick, K. D., Jabs, D. A. 2001. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. *Pharmacoeconomics* 19(12): 1199–1208.
- Kotton, C. N., Kumar, D., Caliendo, A. M., Åsberg, A., Chou, S., Danziger-Isakov, L., et al. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. *Transplantation* 96(4): 333–360.
- Kovack, J. dan Masur, H. 2000. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. *The New England Journal of Medicine Review* 324(19): 1416–1429.
- Lalezari, J. 1995. A randomized, double-blind study of the efficacy and safety of oral ganciclovir for the prevention of cytomegalovirus disease in HIV-infected persons. JP Lalezari for the Syntex Ganciclovir Study Group. *Eighth International Conference on Antiviral Research, Sante Fe, New Mexico*.
- Lalonde, R. G., Boivin, G., Deschênes, J., Hodge, W. G., Hopkins, J. J., Klein, A. H., et al. 2004. Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS. *The Canadian Journal of Infectious Diseases & Medical Microbiology* 15(6): 327–335.
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., et al. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 339: b2700.
- Lichtner, M., Cicconi, P., Vita, S., Cozzi-Lepri, A., Galli, M., Caputo, S. L., et al. 2014. Cytomegalovirus coinfection is associated with increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. *The Journal of Infectious Diseases* 211: 178–186.
- Liu, G. G. dan Hay, J. 2000. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. *Pharmaceutical Research* 17(8): 911–919.
- Maschke, M., Kastrup, O., Diener, H. 2002. CNS manifestations of cytomegalovirus infections. *CNS Drugs* 16(5): 303–315.

- Mattioni, S., Pavie, J., Porcher, R., Scieux, C., Denis, B., De Castro, N., *et al.* 2015. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia. *International Journal of STD and AIDS* 26(5): 306–312.
- Mayaphi, S. H., Brauer, M., Morobadi, D. M., Mazanderani, A. H., Mafuyeka, R. T., Olorunju, S. A. S., *et al.* 2014. Cytomegalovirus viral load kinetics in patients with HIV/AIDS admitted to a medical intensive care unit: A case for pre-emptive therapy. *PLoS ONE* 9(4): e93702.
- McCune, J. M. 2002. Mechanisms of T-cell depletion and regeneration in HIV disease. *Nature* 7(3): 4–9.
- Mizushima, D., Nishijima, T., Gatanaga, H., Tsukada, K., Teruya, K., Kikuchi, Y., *et al.* 2013. Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era. *PLoS ONE* 8(5): e65348.
- Mizushima, D., Nishijima, T., Yashiro, S., Teruya, K., Kikuchi, Y., Katai, N., *et al.* 2015. Diagnostic utility of quantitative plasma cytomegalovirus DNA PCR for cytomegalovirus end-organ diseases in patients with HIV-1 infection. *Journal of Acquired Immune Deficiency Syndromes* 68(2): 140–146.
- Mumtaz, K., Faisal, N., Husain, S., Morillo, A. 2015. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. *American Journal of Transplantation* 15: 472–481.
- Nokta, M. A., Holland, F., De Gruttola, V., Emery, V. C., Jacobson, M. A., Griffiths, P., *et al.* 2002. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. *The Journal of Infectious Diseases* 185(12): 1717–1722.
- Owers, D., Webster, A., Strippoli, G., Kable, K., Hodson, E. 2013. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Review). *Cochrane Database of Systematic Reviews* 2: CD005133.
- Palmisano, L. dan Vella, S. 2011. A brief history of antiretroviral therapy of HIV infection: success and challenges. *Annali dell'Istituto Superiore di Sanita* 47(1): 44–48.
- Razonable, R. R., van, C. H., Brown, R. A., Wilson, J. A., Harmsen, W. S., Wiesner, R. H., *et al.* 2003. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. *The Journal of Infectious Diseases* 187: 1801–1808.
- Razonable, R. dan Paya, C. 2004. Valganciclovir: Oral prevention and treatment of cytomegalovirus in the immunocompromised host. *Expert Opinion on Pharmacotherapy* 2(1): 27-41.
- Rose, D. N. dan Sacks, H. S. 1997. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. *AIDS* 11(7): 883–887.
- Ross, S. A., Novak, Z., Pati, S., Boppana, S. B. 2011. Diagnosis of cytomegalovirus infections. *Infectious Disorders - Drug Targets* 11(5): 466–474.
- Salzberger, B., Hartmann, P., Hanses, F., Uyanik, B., Cornely, O. A., Woehrmann, A., *et al.* 2005. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. *Infection* 33: 345–349.
- Salmon-Ceron, D., Fillet, A. M., Aboulker, J. P., Gerard, L., Houhou, N., Carriere, I., *et*

- al.* 1999. Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. *Clinical Infectious Diseases* 28(4): 901–905.
- Salmon-Céron, D., Mazon, M. C., Chaput, S., Boukli, N., Senechal, B., Houhou, N., *et al.* 2000. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. *AIDS* 14(8): 1041–1049.
- Salmon-Ceron, D. 2001. Cytomegalovirus infection: The point in 2001. *HIV Medicine* 2: 255–259.
- Silva, C. A., Oliveira, A. C. P. de, Vilas-Boas, L., Fink, M. C. D. S., Pannuti, C. S., Vidal, J. E. 2010. Neurologic cytomegalovirus complications in patients with AIDS: retrospective review of 13 cases and review of the literature. *Revista Do Instituto de Medicina Tropical de São Paulo* 52(6): 305–310.
- Simon, V., Ho, D. D., Karim, Q. A. 2006. Seminar HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. *Lancet* 368: 489–504.
- Small, L. N., Lau, J., Snyderman, D. R. 2006. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. *Clinical Infectious Diseases* 43(7): 869–880.
- Spector, S. A., Busch, D. F., Follansbee, S., Squires, K., Lalezari, J. P., Jacobson, M. A., *et al.* 1995. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: A phase I/II study. *The Journal of Infectious Diseases* 171(6): 1431–1437.
- Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., *et al.* 1996. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. *The New England Journal of Medicine* 334: 1491–1497.
- Spector, S. A., Wong, R., Hsia, K., Pilcher, M., Stempien, M. J. 1998. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. *Journal of Clinical Investigation* 101(2): 497–502.
- Spector, S. A., Hsia, K., Cragger, M., Pilcher, M., Cabral, S., Stempien, M. J. 1999. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. *Journal of Virology* 73(8): 7027–7030.
- Sterne, J. A. C., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., *et al.* 2016. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 355: i4919.
- Sterne, J. A., Savovic, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., *et al.* 2019. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 366: 14898.
- Strippoli, G. F. M., Hodson, E. M., Jones, C., Craig, J. C. 2006. Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. *Transplantation* 81(2): 139–145.
- Tan, B. H. 2014. Cytomegalovirus Treatment. *Current Treatment Options in Infectious Diseases* 6(3): 256–270.
- Thoden, J., Potthoff, A., Bogner, J. R., Brockmeyer, N. H., Esser, S., Grabmeier-Pfistershammer, K., *et al.* 2013. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: A guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). *Infection* 41(Suppl 2): S91–S115.
- U.S. Department of Health and Human Services, National Institutes of Health, National

- Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available from: <https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>
- Verbraak, F. D., Boom, R., Wertheim-van Dillen, P. M. E., Van den Horn, G. J., Kijlstra, A., De Smet, M. D. 1999. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease. *British Journal of Ophthalmology* 83(10): 1186–1189.
- Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., *et al.* 2012. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Diakses dari http://www.ohri.ca/programs/clinical_epidemiology/.
- Wohl, David A, Zeng, D., Stewart, P., Glomb, N., Alcorn, T., Jones, S., *et al.* 2005. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. *Journal of Acquired Immune Deficiency Syndromes* 38(5): 538–544.
- Wohl, D. A., Kendall, M. A., Andersen, J., Crumpacker, C., Spector, S. A., Feinberg, J., *et al.* 2009. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: Results of ACTG protocol A5030. *HIV Clinical Trials* 10(3): 143–152.
- Yang, H., Cui, X., Wang, X., Qiu, S., Liu, L. 2017. Clinical outcomes with antiviral prophylaxis or preemptive therapy for cytomegalovirus disease after liver transplantation: A systematic review and meta-analysis. *Journal of Pharmacy and Pharmaceutical Sciences* 20: 15-27.
- Youle, M. S., Gazzard, B. G., Johnson, M. A., Cooper, D. A., Hoy, J. F., Busch, H., *et al.* 1994. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: A double-blind, placebo-controlled study. *AIDS* 8: 641-649.
- Zhang, L. F., Wang, Y. T., Tian, J. H., Yang, K. H., Wang, J. Q. 2011. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: A meta-analysis and systematic review of randomized controlled trials. *Transplant Infectious Disease* 13(6): 622–632.